Zacks Investment Research
06 Mar 2026, 15:35 UTC · 32w ago
Verdict
Headline takes no side. We score TBPH +0.70 — strongly bullish.
+0.70strongly bullish
More positive than 85% of ticker scores this week
Which stocks this story touches
More positive than 85% of ticker scores this week
The article highlights Theravance Biopharma's potential for a trend reversal, citing oversold conditions, strong upward earnings estimate revisions, and a Zacks Rank #2 (Buy), indicating positive sentiment.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
1h ago
+25.4%
Price agrees with the score
$17.03 vs $13.58 close before publication (Mar 5) · not market-adjusted
TBPH chart →
